Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefit

First Page		Document Content
Date: 2015-03-12 23:53:04 Organ failure Immunosuppressants Eculizumab Kidney diseases Hemolytic-uremic syndrome Chronic kidney disease Dialysis Pharmaceutical Benefits Scheme Kidney transplantation Medicine Health Nephrology		Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefit Add to Reading List Source URL: pbs.gov.au Download Document from Source Website File Size: 509,83 KB Share Document on Facebook

	MAJOR ARTICLE Non-O157 Shiga Toxin–Producing Escherichia coli Infections in the United States, 1983–2002 John T. Brooks,1,a Evangeline G. Sowers,1 Joy G. Wells,1 Katherine D. Greene,1 Patricia M. Griffin,1 Robert M. DocID: 1rfmK - View Document
	PREVALENCE OF NON-O157 ENTEROHAEMMORRHAGIC ESCHERICHIA COLI IN RETAIL GROUND BEEF IN THE UNITED STATES M Samadpour1, V Beskhlebnaya1, W Marler2 1 Institute for Environmental Health, United States of America. 2 Marler Cla DocID: 1qWYw - View Document
	Letter Probing genomic diversity and evolution of Escherichia coli O157 by single nucleotide polymorphisms Wei Zhang,1,5,6 Weihong Qi,2 Thomas J. Albert,3 Alifiya S. Motiwala,4 David Alland,4 DocID: 1qLvq - View Document
	PDF Document DocID: 1qgns - View Document
	A q uart e rly N e w s l e t t e r f ro m FSNS Non-O157 STEC caught ‘n the net? By: Dr. Gary C. Smith DocID: 1q2Ze - View Document